百济神州(ONC)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

ONC 百济神州

盘前交易 03-09 08:48:05 EDT

301.12

+8.18

+2.79%

盘前295.00

-6.12-2.03%

08:24 EDT

最高301.49	最低290.93	成交量29.81万
今开292.50	昨收292.94	日振幅3.61%
总市值334.24亿	流通市值257.69亿	总股本1.11亿
成交额8,910万	换手率0.35%	流通股本8,558万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"ONC","market":"US","secType":"STK","nameCN":"百济神州","latestPrice":301.12,"timestamp":1772830800000,"preClose":292.94,"halted":0,"volume":298131,"hourTrading":{"tag":"盘前","latestPrice":295,"preClose":301.12,"latestTime":"08:24 EDT","volume":186,"amount":54686.78627999999,"timestamp":1773059091544,"change":-6.12,"changeRate":-0.020324,"amplitude":0.022217},"delay":0,"changeRate":0.027923806922919393,"floatShares":85577300,"shares":111000000,"eps":0.5204,"marketStatus":"盘前交易","change":8.18,"latestTime":"03-09 08:48:05 EDT","open":292.5,"high":301.49,"low":290.925,"amount":89097680.63103,"amplitude":0.036065,"askPrice":300,"askSize":42,"bidPrice":290,"bidSize":9,"shortable":3,"etf":0,"ttmEps":0.5204,"tradingStatus":1,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1773063000000},"marketStatusCode":1,"adr":0,"adrRate":13,"exchange":"NASDAQ","adjPreClose":301.12,"preHourTrading":{"tag":"盘前","latestPrice":295,"preClose":301.12,"latestTime":"08:24 EDT","volume":186,"amount":54686.78627999999,"timestamp":1773059091544,"change":-6.12,"changeRate":-0.020324,"amplitude":0.022217},"postHourTrading":{"tag":"盘后","latestPrice":299,"preClose":301.12,"latestTime":"19:40 EST","volume":18014,"amount":5424243.57,"timestamp":1772844010616,"change":-2.12,"changeRate":-0.00704,"amplitude":0.00704},"volumeRatio":0.7893859133247242,"impliedVol":0.447,"impliedVolPercentile":0.504},"requestUrl":"/m/hq/s/ONC","defaultTab":"news","newsList":[{"id":"2618009613","title":"营收382亿！创新药“一哥”百济神州，全面扭亏","url":"https://stock-news.laohu8.com/highlight/detail?id=2618009613","media":"蓝鲸财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618009613?lang=zh_cn&edition=full","pubTime":"2026-03-09 10:37","pubTimestamp":1773023833,"startTime":"0","endTime":"0","summary":"2月26日晚，百济神州发布2025年业绩快报。然而，面对业绩全面扭亏，市场反应冷淡。财报发布后，百济神州美股两个交易日跌幅超10%。业绩快报显示，百济神州产品收入377.70亿元，同比增长39.9%，主要由百悦泽、安进授权产品及百泽安销售增长驱动。具体来看，2025年百悦泽全球销售额280.67亿元，同比增长48.8%，创历史新高；百泽安全球销售额52.97亿元，同比增长18.6%。随着适应症持续拓展，百济神州已具备头部药企竞争力。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1772409403580961090","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["06978","159992","06160","ONC","688235"],"gpt_icon":0},{"id":"2617666539","title":"百济神州授出合共2.12万股美国存托股份受限制股份单位","url":"https://stock-news.laohu8.com/highlight/detail?id=2617666539","media":"新浪港股","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617666539?lang=zh_cn&edition=full","pubTime":"2026-03-08 10:31","pubTimestamp":1772937060,"startTime":"0","endTime":"0","summary":"热点栏目\n\n自选股\n数据中心\n行情中心\n资金流向\n模拟交易\n\n客户端\n\n\n　　百济神州（06160）发布公告，于2026年3月2日，董事会薪酬委员会根据2016期权及激励计划的条款授予180名承授人合共2.12万股美国存托股份受限制股份单位。该等受限制股份单位相当于27.56万股股份，约占本公告的日公司发行股份总数的0.02%。\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：卢昱君","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2026-03-08/doc-inhqfsut4635660.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["ONC","BK4588","BK4526","BK4139","LU0307460666.USD","LU1969619763.USD","LU2328871848.SGD","LU0588546209.SGD","688235","LU1251922891.USD","BK0239","LU1719994722.HKD","BK1161","06160","BK1583","BK4585","BK1500","BK1588","LU1770034418.SGD","LU1303224171.USD"],"gpt_icon":0},{"id":"2617068639","title":"百济神州(06160)授出合共2.12万股美国存托股份受限制股份单位","url":"https://stock-news.laohu8.com/highlight/detail?id=2617068639","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617068639?lang=zh_cn&edition=full","pubTime":"2026-03-06 17:20","pubTimestamp":1772788807,"startTime":"0","endTime":"0","summary":"智通财经APP讯，百济神州(06160)发布公告，于2026年3月2日，董事会薪酬委员会根据2016期权及激励计划的条款授予180名承授人合共2.12万股美国存托股份受限制股份单位。该等受限制股份单位相当于27.56万股股份，约占本公告的日公司发行股份总数的0.02%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1411013.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","BK4588","06160","688235","BK4526","BK4585","BK0239","LU1719994722.HKD","LU1969619763.USD","BK4139","LU1303224171.USD","LU1251922891.USD","ONC","LU0307460666.USD","LU2328871848.SGD","BK1583","BK1588","LU0588546209.SGD","BK1500","LU1770034418.SGD"],"gpt_icon":0},{"id":"2617501282","title":"首批！“调出”科创板成长层，涉寒武纪、百济神州等","url":"https://stock-news.laohu8.com/highlight/detail?id=2617501282","media":"券商中国","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617501282?lang=zh_cn&edition=full","pubTime":"2026-03-06 09:01","pubTimestamp":1772758860,"startTime":"0","endTime":"0","summary":"近日，多家科创板成长层企业发布了2025年度业绩快报。包括寒武纪、百济神州等在内的企业纷纷扭亏为盈。根据科创板成长层的相关规则，上述企业预计将在年报正式披露后摘除特殊标识，退出科创板成长层。据悉，科创板成长层于去年6月份推出，这将是首批“退层”企业。公司应当在披露年度报告的同时，披露符合条件且将被调出科创成长层的公告。这4家在年报正式披露后或也将被调出科创成长层。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://mp.weixin.qq.com/s?__biz=MzA3NjM5MjIwOQ==&mid=2652257320&idx=2&sn=1a30f506242618baaaeaa39a9f05819f&chksm=85508ad42695f69dd234ae51d881f82448e6fb0665374c5f128426719f4897d8619a637188ae&scene=0#rd","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"weixin_highlight","symbols":["LU1251922891.USD","BK4139","BK1161","688235","BK0231","LU1969619763.USD","ONC","SGXZ49509284.SGD","LU0588546209.SGD","SG9999001069.SGD","SG9999003461.SGD","BK4585","LU1719994722.HKD","BK1500","BK1588","LU1303224171.USD","LU2778985437.USD","BK4526","LU1770034418.SGD","SG9999002950.SGD","SGXZ90724238.SGD","SG9999006597.SGD","LU0307460666.USD","LU2328871848.SGD","BK0239","LU2476274308.USD","BK1583","688256","06160","159982","LU2476274720.SGD","SG9999001051.SGD","BK4588","SGXZ81163826.USD","SG9999001093.SGD"],"gpt_icon":1},{"id":"2617661566","title":"百济神州“增长之问”：泽布替尼美国市占率登顶后，下一个五年能走多远？","url":"https://stock-news.laohu8.com/highlight/detail?id=2617661566","media":"动脉新医药","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617661566?lang=zh_cn&edition=full","pubTime":"2026-03-04 17:33","pubTimestamp":1772616836,"startTime":"0","endTime":"0","summary":"百济神州方面指出。这种“增量不减”的态势，离不开泽布替尼全球化布局的深化。其中2025年Q4，泽布替尼的中国地区增速有所下滑，销售额8600万美元，环比下降6.87%，欧洲地区销售额1.67亿美元，环比增长2.45%。2025年Q3，泽布替尼的美国市场占有率达到33.8%，超过伊布替尼成为第一名，全球市场占有率在2025年Q4突破30%。百济神州方面表示。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202603041812149542f65c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202603041812149542f65c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4585","BK4139","BK4588","BK4526","ONC"],"gpt_icon":0},{"id":"2616580089","title":"超130家药企亏损太惊人，318家晒2025成绩单！百济神州、特宝生物净利润首破10亿，奇正、千金……亮眼","url":"https://stock-news.laohu8.com/highlight/detail?id=2616580089","media":"米内网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616580089?lang=zh_cn&edition=full","pubTime":"2026-03-04 16:32","pubTimestamp":1772613166,"startTime":"0","endTime":"0","summary":"截至目前，医药企业已有318家披露成绩单，其中近130家是业绩快报，华润三九、奇正藏药、千金药业等业绩双涨。此外，有超过130家亏损，智飞生物首亏超过100亿元。17家净利润超10亿，华润三九、奇正、千金……其中，药明康德以191.51亿元领跑，三生国健、艾力斯首次晋身20亿元梯队，百济神州、特宝生物首次突破10亿元大关。从亏损金额来看，1亿元及以上占比超6成，智飞生物亏损最多，超过100亿元，也是公司上市以来首亏。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260304163930a44a75e3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260304163930a44a75e3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06160","ONC"],"gpt_icon":0},{"id":"1146097023","title":"异动解读 | 百济神州盘中大跌5.34%，港股创新药板块回调资金“利好出尽”撤离","url":"https://stock-news.laohu8.com/highlight/detail?id=1146097023","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1146097023?lang=zh_cn&edition=full","pubTime":"2026-03-03 22:53","pubTimestamp":1772549595,"startTime":"0","endTime":"0","summary":"百济神州（ONC）今日盘中股价大跌5.34%，引起了市场的广泛关注。消息面上，此次下跌与港股创新药板块整体大幅回调有关，百济神州在板块中领跌。尽管公司此前发布了强劲的2025年业绩，实现营业总收入同比增长40.4%并成功扭亏为盈，但部分资金选择“利好出尽”式撤离，这是A股和港股市场常见的博弈行为。同时，市场对创新药企的定价逻辑正在发生根本性转变，从单纯看重管线储备转向研发能力、商业化能力与合规能力的综合考量。资金面上，外资持续流出港股医药板块，南向资金转向科技、高股息板块，港股创新药ETF近期出现净赎回，资金获利了结情绪集中释放，共同导致了股价的短期承压。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["ONC"],"gpt_icon":0},{"id":"2616297723","title":"首次全年盈利，百济神州为何股价三地齐跌？","url":"https://stock-news.laohu8.com/highlight/detail?id=2616297723","media":"中国新闻网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616297723?lang=zh_cn&edition=full","pubTime":"2026-03-03 22:49","pubTimestamp":1772549340,"startTime":"0","endTime":"0","summary":"中新网北京3月3日电(记者赵方园)一度被冠以“烧钱一哥”的A股创新药龙头百济神州，终于在2025年迎来了历史性转折。近期，百济神州发布2025年度业绩快报，报告期内实现营业总收入382.05亿元，同比增长40.4%；归属于上市公司股东的净利润14.22亿元。而在2024年同期，公司亏损49.78亿元。这是百济神州成立十六年以来首次实现全年盈利。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202603033660707240.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603033660707240.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["ONC","BK4139","LU1969619763.USD","BK1500","LU1303224171.USD","BK4526","BK1588","BK1161","BK1583","LU0588546209.SGD","688235","06160","BK4585","LU1719994722.HKD","LU0307460666.USD","BK0239","LU1251922891.USD","BK4588","LU1770034418.SGD","LU2328871848.SGD"],"gpt_icon":0},{"id":"1197802256","title":"异动解读 | 百济神州盘前大跌5.20%，港股创新药板块回调资金“利好出尽”撤离","url":"https://stock-news.laohu8.com/highlight/detail?id=1197802256","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1197802256?lang=zh_cn&edition=full","pubTime":"2026-03-03 22:02","pubTimestamp":1772546577,"startTime":"0","endTime":"0","summary":"百济神州（ONC）今日盘前股价大跌5.20%，引起了市场的广泛关注。消息面上，此次下跌与港股创新药板块整体大幅回调有关，百济神州在板块中领跌。尽管公司此前发布了强劲的2025年业绩，但部分资金选择“利好出尽”式撤离，这是A股和港股市场常见的博弈行为。同时，市场对创新药企的定价逻辑正在发生根本性转变，从单纯看重管线储备转向研发能力、商业化能力与合规能力的综合考量。百济神州2025年业绩显示，公司实现营业总收入同比增长40.4%，并成功扭亏为盈。然而，在财报公布后，市场资金流向的变化和板块情绪的调整，共同导致了股价的短期承压。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["ONC"],"gpt_icon":0},{"id":"2616316707","title":"交银国际：百济神州(06160)上季产品销售强势 维持“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2616316707","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616316707?lang=zh_cn&edition=full","pubTime":"2026-03-03 15:09","pubTimestamp":1772521742,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，交银国际发布研报称，百济神州去年第四季泽布替尼销售额11亿美元(下同)，同比及按季分别升38%及10%，美国销售额8.45亿，同比及按季分别升37%及14%。在1LCLL患者中，泽布在BTK品类中的份额约占一半、在所有治疗药物中约占四分之一。公司指引2026年收入62亿至64亿，GAAP经营费用47亿至49亿元，毛利率在80%区间的高位，non-GAAP净利润14亿至15亿元，维持“买入”评级。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1409396.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06160","688235","ONC"],"gpt_icon":0},{"id":"2616318402","title":"百济神州业绩亮丽：砸40%营收做研发、狂赚逾14亿","url":"https://stock-news.laohu8.com/highlight/detail?id=2616318402","media":"Ofweek光电信息网","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616318402?lang=zh_cn&edition=full","pubTime":"2026-03-03 10:37","pubTimestamp":1772505420,"startTime":"0","endTime":"0","summary":"2025年，百济神州营业总收入站上382.05亿元的新台阶，同比增长40.4%，归母净利润达到14.22亿元，2024年亏损49.78亿元。2025年能够跨过盈亏平衡线，离不开百济神州砸钱做研发，2022年至2024年公司研发费用均超过100亿元。到了2025年研发投入持续增加，百济神州2025年全年研发费用达21.46亿美元，同比增长10%，占同期营业收入比例约为40%。2月26日晚，百济神州发布了2026年业绩预测，公司预测2026年营业收入将介于436亿元至450亿元之间，较2025年营业收入的增速在14.12%与17.79%之间。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260303104312a44472d9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260303104312a44472d9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06160","ONC"],"gpt_icon":0},{"id":"2616783391","title":"国金证券：维持百济神州(06160)“买入”评级 早研管线步入收获期","url":"https://stock-news.laohu8.com/highlight/detail?id=2616783391","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616783391?lang=zh_cn&edition=full","pubTime":"2026-03-03 10:36","pubTimestamp":1772505397,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，国金证券发布研报称，维持百济神州“买入”评级。公司核心产品高速放量，研发管线有望迎来密集催化。国金证券主要观点如下：业绩简评2026年2月26日公司发布2025年业绩快报，全年实现总收入53亿美元，实现GAAP净利润2.87亿美元;其中25Q4实现总收入15亿美元，实现GAAP净利润6650万美元。风险提示商业化进展不及预期风险、市场竞争加剧风险、临床试验进展不及预期风险、产品上市审评进展不及预期风险。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1409307.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06160","ONC","688235"],"gpt_icon":0},{"id":"2616182363","title":"【私募调研记录】景林资产调研百济神州","url":"https://stock-news.laohu8.com/highlight/detail?id=2616182363","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616182363?lang=zh_cn&edition=full","pubTime":"2026-03-03 08:10","pubTimestamp":1772496652,"startTime":"0","endTime":"0","summary":"根据市场公开信息及3月2日披露的机构调研信息，知名私募景林资产近期对1家上市公司进行了调研，相关名单如下：1)百济神州调研纪要：公司在2025年实现净利润和正向自由现金流，经营活动净现金达11亿美元，自由现金流为正。这些考虑是上海景林做投资决定和估值过程中的核心。上海景林所管理的基金均给投资人创造了丰厚的长期回报。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260303082402a69ac076&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260303082402a69ac076&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4526","ONC","BK4588","BK4585","BK4139","06160"],"gpt_icon":0},{"id":"2616056538","title":"【券商聚焦】交银国际维持百济神州(06160)买入评级 指4Q25产品销售强势","url":"https://stock-news.laohu8.com/highlight/detail?id=2616056538","media":"金吾财讯","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616056538?lang=zh_cn&edition=full","pubTime":"2026-03-02 10:13","pubTimestamp":1772417607,"startTime":"0","endTime":"0","summary":"金吾财讯 | 交银国际研报指，百济神州 4Q25泽布替尼销售额11亿，同/环比+38%/+10%，美国销售额8.45亿。在1LCLL患者中，泽布在BTK品类中的份额约占一半、在所有治疗药物中约占1/4。4Q25毛利率同比提升4.7ppts至90.5%，SG&A费用率同比下降7.7ppts，non-GAAP净利润同比大增至2.25亿。公司指引2026年收入62-64亿，GAAP经营费用4749亿，毛利率在80%区间的高位，non-GAAP净利润14-15亿。泽布+索托固定周期疗法首个同机制对照III期近期已启动。","market":"sg","thumbnail":"https://static.szfiu.com/news/20250106/ZGNkM2E3NDVjMTk0N2Q5ZDk4NjYxNjc1YjA4NjMzOTA5MjkwMDE=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250106/ZGNkM2E3NDVjMTk0N2Q5ZDk4NjYxNjc1YjA4NjMzOTA5MjkwMDE=.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1975682","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ONC","688235","06160"],"gpt_icon":0},{"id":"2616871468","title":"首次实现全年盈利 百济神州2025年营收增长超四成","url":"https://stock-news.laohu8.com/highlight/detail?id=2616871468","media":"经济参考报","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616871468?lang=zh_cn&edition=full","pubTime":"2026-03-02 04:50","pubTimestamp":1772398248,"startTime":"0","endTime":"0","summary":"近日，创新药龙头百济神州（688235.SH/06160.HK）发布的2025年度业绩快报显示，公司全年实现营业总收入382.05亿元，同比大幅增长40.4%；实现归属于母公司所有者的净利润达14.22亿元，较上年同期的净亏损49.78亿元实现扭亏为盈。这是百济神州首次实现年度盈利，或标志着这家创新药企迈入可持续盈利的新发展阶段。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202603023657828489.html","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603023657828489.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["688235","06160","ONC"],"gpt_icon":0},{"id":"2614789759","title":"首度盈利，股价为何崩了？百济神州叫好不叫座的“盈利魔咒”","url":"https://stock-news.laohu8.com/highlight/detail?id=2614789759","media":"华夏时报网","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614789759?lang=zh_cn&edition=full","pubTime":"2026-02-28 13:21","pubTimestamp":1772256083,"startTime":"0","endTime":"0","summary":"2025年，对于素有“创新药一哥”之称的百济神州而言，无疑是载入史册的一年。这份由公司于2月26日晚间交出的年度成绩单，在“归属于母公司所有者的净利润”这一关键指标上，终于迎来了期盼已久的正向数字——14.22亿元。从长达数年的巨额亏损到首次全年盈利，从单纯“烧钱”研发到初步实现自我“造血”，百济神州似乎终于迎来了宣扬已久的“商业化元年”的曙光。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202602283657400898.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202602283657400898.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0239","LU2328871848.SGD","BK4139","LU1969619763.USD","BK1161","688235","ONC","LU1770034418.SGD","BK1583","BK4588","LU1719994722.HKD","BK4526","LU0588546209.SGD","BK1588","BK1500","BK4585","LU1303224171.USD","LU0307460666.USD","LU1251922891.USD","06160"],"gpt_icon":0},{"id":"2614856787","title":"百济神州迎来“幸福的烦恼” 公司全球研发负责人汪来：“牌”多的时候，不见得每一张都得自己打","url":"https://stock-news.laohu8.com/highlight/detail?id=2614856787","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614856787?lang=zh_cn&edition=full","pubTime":"2026-02-27 21:19","pubTimestamp":1772198372,"startTime":"0","endTime":"0","summary":"“我们现在的痛苦和快乐就是管线太强劲，太强劲了以后我们有很多舍不得。你不能slowdown（放慢速度）了，还得快步地往前跑。这里面的确有一个平衡的问题。”2月27日上午，百济神州在线上召开2025年年度业绩路演小组会，公司总裁兼首席运营官吴晓滨说了这样一段话。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202602273656980575.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202602273656980575.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1583","BK1588","BK4526","LU1303224171.USD","LU1969619763.USD","BK4139","LU1251922891.USD","LU0588546209.SGD","BK0239","LU1719994722.HKD","LU0307460666.USD","BK1500","LU2328871848.SGD","BK4588","ONC","688235","06160","BK1161","BK4585","LU1770034418.SGD"],"gpt_icon":0},{"id":"2614083875","title":"首度全年盈利的百济神州，与川股百利天恒有一个共同点：都被这些公募基金重仓","url":"https://stock-news.laohu8.com/highlight/detail?id=2614083875","media":"金融投资报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614083875?lang=zh_cn&edition=full","pubTime":"2026-02-27 16:51","pubTimestamp":1772182279,"startTime":"0","endTime":"0","summary":"金融投资报记者贺梦璐“盈利了，但市值却跌破3000亿元。”这或许是百济神州发布2025年度业绩快报后，留给资本市场的最大困惑。金融投资报记者注意到，当投资者将目光转向其股东名单时，一个有意思的巧合开始浮现：那些重仓百济神州的公募基金，同样也对川股百利天恒青睐有加。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202602273656715059.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU0588546209.SGD","688235","BK4526","BK1583","LU1303224171.USD","BK0239","LU1719994722.HKD","02615","BK1500","06160","91194","LU1969619763.USD","688506","BK4585","LU2328871848.SGD","BK1588","LU0307460666.USD","BK4139","LU1770034418.SGD","BK4588","LU1251922891.USD","BK1161","ONC"],"gpt_icon":0},{"id":"2614860298","title":"群益证券：维持百济神州(06160)“买入”的评级 首年实现盈利且商业化效果显现","url":"https://stock-news.laohu8.com/highlight/detail?id=2614860298","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614860298?lang=zh_cn&edition=full","pubTime":"2026-02-27 14:28","pubTimestamp":1772173726,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，群益证券发布研报称，维持百济神州“买入”的评级。群益证券主要观点如下：公司业绩快报公司发布2025年业绩快报，实现营业总收入382.1亿元，同比增长40.4%，其中产品收入377.7亿元，YOY+39.9%;实现归母净利润14.2亿元，公司业绩符合预期。其中Q4单季度实现营收106.1亿元，YOY+31.3%,录得归母净利润2.8亿元。另外，百泽安销售53亿元,YOY+19%,主要是在中国新适应获批及入院量增加。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1408078.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["ONC","06160","688235","161027"],"gpt_icon":0},{"id":"2614029001","title":"百济神州穿越“死亡谷”：首次实现全年盈利 下一波增长点在哪？","url":"https://stock-news.laohu8.com/highlight/detail?id=2614029001","media":"21世纪经济报道","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614029001?lang=zh_cn&edition=full","pubTime":"2026-02-27 10:27","pubTimestamp":1772159237,"startTime":"0","endTime":"0","summary":"2月26日晚间，百济神州（纳斯达克代码：BGNE；香港联交所代码：06160.HK；上交所代码：688235.SH）发布了其2025年度业绩快报。报告期内，公司营业总收入达382.05亿元，同比增长40.4%。得益于产品收入增长和费用管理推动的经营效率提升，公司归属于母公司所有者的净利润达14.22亿元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202602273656435915.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202602273656435915.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU1719994722.HKD","BK0239","LU1770034418.SGD","BK1588","BK1583","BK4139","LU1251922891.USD","LU0588546209.SGD","LU2328871848.SGD","BK4585","BK1161","BK4588","06160","LU1303224171.USD","BK1500","688235","LU1969619763.USD","BK4526","ONC","LU0307460666.USD"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.beonemedicines.com","stockEarnings":[{"period":"1week","weight":-0.0501},{"period":"1month","weight":-0.1445},{"period":"3month","weight":-0.0675},{"period":"6month","weight":-0.119},{"period":"1year","weight":0.1718},{"period":"ytd","weight":-0.0089}],"compareEarnings":[{"period":"1week","weight":-0.0198},{"period":"1month","weight":-0.0201},{"period":"3month","weight":-0.0194},{"period":"6month","weight":0.0388},{"period":"1year","weight":0.174},{"period":"ytd","weight":-0.014}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"　　百济神州有限公司的主营业务是研究、开发、生产以及商业化创新型药物。公司的主要产品是百悦泽、百泽安、百汇泽、安加维、倍利妥、凯洛斯、萨温珂、凯泽百、普贝希（安维汀生物类似药）、百拓维（注射用戈舍瑞林微球）、泰菲乐（达拉非尼）、迈吉宁（曲美替尼）、维全特（帕唑帕尼）、飞尼妥（依维莫司）、赞可达（塞瑞替尼）。截至本报告期末，公司及其控股子公司拥有的发明专利包括美国发明专利64个、中国发明专利67个、日本发明专利30个、欧洲发明专利15个及其他国家或地区的发明专利135个。","yearOnYearQuotes":[{"month":1,"riseRate":0.6,"avgChangeRate":0.083709},{"month":2,"riseRate":0.6,"avgChangeRate":0.027535},{"month":3,"riseRate":0.363636,"avgChangeRate":-0.0281},{"month":4,"riseRate":0.4,"avgChangeRate":0.021288},{"month":5,"riseRate":0.4,"avgChangeRate":-0.019094},{"month":6,"riseRate":0.5,"avgChangeRate":0.012468},{"month":7,"riseRate":0.8,"avgChangeRate":0.147208},{"month":8,"riseRate":0.6,"avgChangeRate":0.034201},{"month":9,"riseRate":0.6,"avgChangeRate":0.069537},{"month":10,"riseRate":0.5,"avgChangeRate":-0.004517},{"month":11,"riseRate":0.6,"avgChangeRate":0.063715},{"month":12,"riseRate":0.3,"avgChangeRate":-0.043663}],"exchange":"NASDAQ","name":"百济神州","nameEN":"BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"百济神州(ONC)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供百济神州(ONC)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"百济神州,ONC,百济神州股票,百济神州股票老虎,百济神州股票老虎国际,百济神州行情,百济神州股票行情,百济神州股价,百济神州股市,百济神州股票价格,百济神州股票交易,百济神州股票购买,百济神州股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"百济神州(ONC)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供百济神州(ONC)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}